EA
COLL icon

Evolution Advisers’s Collegium Pharmaceutical COLL Stock Holding History

Evolution Advisers’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+6
New +$205 ﹤0.01% 357

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Evolution Advisers's COLL Position: Q2 2026 in Review

Evolution Advisers opened a new position in Collegium Pharmaceutical (COLL) in Q2 2026: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #357 among its holdings.

278 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Evolution Advisers held 6 shares of Collegium Pharmaceutical worth $0 as of Q2 2026.
  • Collegium Pharmaceutical was a new Evolution Advisers position in Q2 2026.
  • Collegium Pharmaceutical made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #357 holding.
  • 278 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.